iPS Cells & Regenerative Medicine– category –
-
Australian iCamuno Biotherapeutics Launches Clinical Trial for Parkinson’s with ‘Hypoimmune Neural Cell Therapy’ Avoiding Immunosuppression
News Hub (Australia) Australia Overview Supported by A$4.6 million from the Australian government's Medical Research Future Fund, iCamuno Biotherapeutics has initiated a five-year research program to evaluate a novel stem cell therapy fo... -
FDA Approves Orca-T, First Regulatory T-Cell Therapy to Improve Chronic GVHD-Free Survival in Blood Cancer Patients Undergoing Allogeneic HSCT
American Society of Clinical Oncology (ASCO) Post USA Overview The US FDA has approved Orca-T (Tregzi, Orca Bio), the first regulatory T-cell (Treg)-based immunotherapy to improve chronic graft-versus-host disease (GVHD)-free survival in... -
Fate Therapeutics to Present iPSC-Derived Cell Immunotherapy Pipeline Progress at Investor Conferences
Fate Therapeutics, Inc. USA Overview Fate Therapeutics announced its participation in several upcoming investor conferences during Q3 2026. The clinical-stage biopharmaceutical company focuses on developing innovative 'off-the-shelf' iPS... -
A2 Biotherapeutics’ CAR T-Cell Therapy A2B543 Receives FDA Fast Track Designation for Advanced Solid Tumors
OncLive USA Overview A2 Biotherapeutics Inc.'s autologous CAR T-cell therapy, A2B543, has been granted FDA Fast Track designation for adults with recurrent unresectable, locally advanced, or metastatic solid tumors who are HLA-A*02 posit... -
China’s NMPA Grants World’s First Approval for Solid Tumor CAR T-Cell Therapy Satri-cel Targeting CLDN18.2 Positive Gastric Cancer
OncLive USA Overview OncLive's June 2026 GI oncology regulatory roundup highlights China's NMPA approval of CARsgen Therapeutics' satricabtagene autoleucel (satri-cel), the first solid tumor CAR T-cell therapy for Claudin18.2-positive ad... -
Cellares’ Cell Shuttle Platform Accepted into FDA’s Inaugural Manufacturing PreCheck Cohort, First and Only Cell Therapy Platform to Receive Designation
BioSpace USA Overview Cellares announced its acceptance into the FDA's inaugural 'Manufacturing PreCheck Pilot Program,' as the sole cell therapy platform among seven companies nationwide. Its automated, end-to-end Cell Shuttle platform ... -
Vertex’s CRISPR Gene Therapy CASGEVY Gains Expanded FDA Approval for Sickle Cell Disease and Beta Thalassemia in Children Ages 2 and Older
Vertex Pharmaceuticals USA Overview Vertex Pharmaceuticals announced the US FDA has approved an expanded indication for its gene therapy, CASGEVY® (exagamglogene autotemcel), for treating sickle cell disease or transfusion-dependent beta... -
UniXell’s iPSC-Derived Parkinson’s Therapy UX-DA003 Cleared for US Clinical Trials by FDA
Parkinson's News Today USA Overview UniXell Biotechnology has received FDA Investigational New Drug (IND) clearance for UX-DA003, an allogeneic iPSC-derived dopaminergic neural progenitor cell therapy for Parkinson's disease, enabling th... -
KATU News: Experimental Gene Therapy Targeting Aging Cells Based on Yamanaka Factors Enters Early Glaucoma Trials
KATU News (YouTube) USA Overview According to KATU News, an experimental gene therapy inspired by Professor Shinya Yamanaka's Nobel Prize-winning iPSC research is targeting aging cells and holds the potential to open a new chapter in agi... -
Amerigo Scientific Unveils Advanced iPSC-Derived Cells to Propel Biomedical Research and Cell Therapy
24-7PressRelease.com (Amerigo Scientific発表) USA Overview Amerigo Scientific has launched a new portfolio of high-purity, iPSC-derived cells, including advanced reporter lines, aimed at accelerating biomedical research and cell therapy ...
